OptiNose, Inc. (OPTN)
After hours:
| Previous close | 0.9253 |
| Open | 1.2400 |
| Bid | 0.8996 x 200 |
| Ask | 0.9457 x 100 |
| Day's range | 0.8903 - 1.2500 |
| 52-week range | 0.8550 - 2.1000 |
| Volume | |
| Avg. volume | 618,543 |
| Market cap | 101.95M |
| Beta (5Y monthly) | -0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.75 |
GlobeNewswireOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps
Simply Wall St.OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders should be happy to see the share price up 13% in the last quarter. But will...
- GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will
